USPTO serial 97298306
OLPUNTRA
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- PRIZANT, JAMES
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OLPUNTRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Max Moskowitz
MAX MOSKOWITZ OSTROLENK FABER LLP8TH FLOOR845 3RD AVENEW YORK, NY 10022Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders and of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; Pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 3, 2023 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Jan 3, 2023 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Dec 28, 2022 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Dec 27, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 27, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 7, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 21, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 19, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 11, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 10, 2022 | NWAP | NEW APPLICATION ENTERED | — |